

FIGURE 1

Subjective Drug Effects Scale: Liking This Feeling
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 2

Subjective Drug Effects Scale: Liking This Feeling
Area Under the Curve for Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 3

Subjective Drug Effects Scale: Good Effects
Maximum Change from Baseline (PDmax)
Population: Valid for pharmacodynamic
treatment-by-period Means




FIGURE 4

Subjective Drug Effects Scale: Good Effects
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-period Interaction




FIGURE 5

Subjective Drug Effects Scale: Feeling Sick
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-period Means





FIGURE 6

Subjective Drug Effects Scale: Feeling Sick
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ●-●-● NTX Placebo ○-○-○ 0.25 mg NTX ○-○-○ 0.50 mg NTX

FIGURE 7

Subjective Drug Effects Scale: Bad Effects
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
treatment-by-period Means





FIGURE 8

Subjective Drug Effects Scale: Bad Effects
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment:
 NTX placebo
 25 mg NTX
 50 mg NTX

FIGURE 9

Subjective Symptom Rating Scale: Antagonist
Maximum Change from Baseline (pDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 10

Subjective Symptom Rating Scale: Antagonist
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 11

Pupil Diameter (mm)
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means





FIGURE 12

Pupil Diameter (mm)
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: •-•-• NTX Placebo 0-0-0 25 mg NTX 0-0-0 50 mg NTX